Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)

Trial Profile

A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Lenzilumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Acronyms ZUMA-19
  • Sponsors Gilead Sciences; Kite Pharma
  • Most Recent Events

    • 04 Nov 2020 According to a Humanigen media release, this trial will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition.
    • 30 Jun 2020 According a Humanigen media release, the first patient has been infused in the study.
    • 11 May 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Apr 2020 to 1 Jun 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top